CPX-351

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Phase IB/II of CPX-351 for Relapse Prevention in AML

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome